Financials data is unavailable for this security.
View more
Year on year Biosyent Inc grew net income 18.35% from 5.46m to 6.46m primarily through revenue growth (27.93m to 31.59m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 13.12% growth in revenues contributed enough to still see net income improve.
| Gross margin | 79.77% |
|---|---|
| Net profit margin | 21.14% |
| Operating margin | 24.63% |
| Return on assets | 17.66% |
|---|---|
| Return on equity | 20.88% |
| Return on investment | 20.16% |
More ▼
Cash flow in CADView more
In 2023, Biosyent Inc did not generate a significant amount of cash. However, the company earned 5.05m from its operations for a Cash Flow Margin of 16.00%. In addition the company generated 883.85k cash from investing, though they paid out 5.78m more in financing than they received.
| Cash flow per share | 0.6387 |
|---|---|
| Price/Cash flow per share | 16.56 |
| Book value per share | 3.06 |
|---|---|
| Tangible book value per share | 2.96 |
More ▼
Balance sheet in CADView more
| Current ratio | 6.13 |
|---|---|
| Quick ratio | 4.90 |
| Total debt/total equity | 0.0319 |
|---|---|
| Total debt/total capital | 0.0309 |
More ▼
Growth rates in CAD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 300.00% and 21.96%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.46% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 28.33% |
| EPS growth(5 years) | 6.22 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 39.42 |
More ▼
